@inbook{6fa1e69e185346f9980d431f9c7f12df,
title = "Cancer immunotherapy: The dawn of antibody cocktails",
abstract = "Since the approval of the first monoclonal antibody (mAb), rituximab, for hematological malignancies, almost 30 additional mAbs have been approved in oncology. Despite remarkable advances, relatively weak responses and resistance to antibody monotherapy remain major open issue. Overcoming resistance might require combinations of drugs blocking both the major target and the emerging secondary target. We review clinically approved combinations of antibodies and either cytotoxic regimens (chemotherapy and irradiation) or kinase inhibitors. Thereafter, we focus on the most promising and currently very active arena that combines mAbs inhibiting immune checkpoints or growth factor receptors. Clinically approved and experimental oligoclonal mixtures of mAbs targeting different antigens (hetero-combinations) or different epitopes of the same antigen (homo-combinations) are described. Effective oligoclonal mixtures of antibodies that mimic the polyclonal immune response will likely become a mainstay of cancer therapy.",
author = "Ilaria Marrocco and Donatella Romaniello and Yosef Yarden",
note = "Our laboratory has been supported by the European Research Council, the Israel Science Foundation, the Israel Cancer Research Fund, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. I.M. and D.R. received the Sergio Lom-broso Fellowship for postdoctoral cancer research. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. Our studies were performed in the Marvin Tanner Laboratory for Research on Cancer. ",
year = "2019",
doi = "10.1007/978-1-4939-8958-4_2",
language = "English",
isbn = "978-1-4939-8957-7",
series = "Methods in Molecular Biology",
publisher = "Humana Press",
pages = "11--51",
editor = "Steinitz, {Michael Steinitz}",
booktitle = "Human Monoclonal Antibodies",
address = "United States",
}